{"classes":[{"categories":[{"measurements":[{"comment":"Median and the upper bound of the 95% CI were not estimable due to insufficient number of participants and/or events.","groupId":"OG000","lowerLimit":"27.0","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"TTP was defined as the number of days from the date of first infusion (Day 1) to the date of first record of disease progression. Disease progression (IMWG criteria 2011): increase of \\>=25 percent (%) from lowest response level in Serum M-component and/or (the absolute increase must be \\>=0.5 g/dL) Urine M-component and/or (the absolute increase must be \\>=200 mg/24 hour; only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase must be \\>10 mg/dL; Bone marrow plasma cell percentage: the absolute % must be \\>=10 %; Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \\>11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder. Median TTP was estimated by using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants administered with daratumumab 16 mg/kg on Day 1, 8, 15, 22 (cycle 1), Days 1, 8, 15, and 22 (cycle 2), Days 1 and 15 (Cycles 3 to 6), Day 1 (Cycle 7+) along with Lenalidomide 25 milligram (mg) on Day 1 to 21 of each 28-day cycle and Dexamethasone 40 mg (weekly) and may be reduced to 20 mg (weekly after cycle 6 at the investigator's discretion). Each treatment cycle consists of 28 days.","id":"OG000","title":"Phase 2: 16 mg/kg Daratumumab + Lenalidomide and Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"ITT population analysis set included all enrolled participants who signed the informed consent during Phase 2.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Phase 2: Time to Progression (TTP)","type":"SECONDARY","unitOfMeasure":"Months"}